CIK 0001604821
- Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 010894487
- Phone
- +1 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-18 | Sheena Jonathan Director | Sale 10b5-1 | −152 | $166.01 | $25K | 47,630 |
| 2024-12-18 | Sheena Jonathan Director | Sale 10b5-1 | −852 | $167.07 | $142K | 46,778 |
| 2024-12-18 | Sheena Jonathan Director | Sale 10b5-1 | −496 | $168.02 | $83K | 46,282 |
| 2024-12-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −28,681 | $164.61 | $4.7M | 2,520,499 |
| 2024-12-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −75,323 | $165.45 | $12.5M | 2,445,176 |
| 2024-12-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −45,769 | $166.45 | $7.6M | 2,399,407 |
| 2024-12-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −4,927 | $167.39 | $825K | 2,394,480 |
| 2024-12-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −5,300 | $168.35 | $892K | 2,389,180 |
| 2024-12-10 | Chapman Rowan E Director | Sale | −1,767 | $170.24 | $301K | 6,202 |
| 2024-12-09 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Grant or award 10b5-1 | +5,752 | $7.45 | $43K | 116,447 |
| 2024-12-09 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Grant or award 10b5-1 | +3,323 | $12.85 | $43K | 119,770 |
| 2024-12-09 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −4,858 | $166.59 | $809K | 114,912 |
| 2024-12-09 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −5,752 | 0 | ||
| 2024-12-09 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −3,323 | 0 | ||
| 2024-12-05 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Exercise or conversion | +68,496 | $5.40 | $370K | 2,549,180 |
| 2024-12-05 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Exercise or conversion · Stock Option (right to buy) | −68,496 | 0 | ||
| 2024-12-02 | BOTHA ROELOF Director | Sale | −8,783 | $166.88 | $1.5M | 1,303,477 |
| 2024-12-02 | BOTHA ROELOF Director | Sale | −10,447 | $167.59 | $1.8M | 1,293,030 |
| 2024-12-02 | BOTHA ROELOF Director | Sale | −16,853 | $168.73 | $2.8M | 1,276,177 |
| 2024-12-02 | BOTHA ROELOF Director | Sale | −40,171 | $169.78 | $6.8M | 1,236,006 |
Page 61 of 85 · 1,682 trades